Diabetic Retinopathy Candesartan Trials - DIRECT

Study identifier:D2453C00045

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Effects of candesartan cilexetil (candesartan) on diabetic retinopathy in type 1 diabetic patients without retinopathy.

Medical condition

Type 1 Diabetes

Phase

Phase 3

Healthy volunteers

No

Study drug

candesartan cilexetil

Sex

All

Actual Enrollment

5238

Study type

Interventional

Age

18 Years - 50 Years

Date

Study Start Date: 01 Jun 2001
Primary Completion Date: 01 Apr 2008
Study Completion Date: 01 Apr 2008

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Takeda

Inclusion and exclusion criteria